GlobeNewswire Inc | May 25, 2021 04:10PM EDT

May 25, 2021

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Robert Ang, MBBS, MBA, Vors President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vors Chief Financial Officer, are scheduled to present at the following conferences:

Jefferies Virtual Healthcare ConferenceDate: Tuesday, June 1, 2021Time: 4:00 PM ET

Goldman Sachs 42nd Annual Global Healthcare Conference Date: Wednesday, June 9, 2021Time: 9:40 AM ET

A live webcast of the presentations can be accessed via the Investors section of the Company's website at www.vorbio.com. An archived replay will also be available on the Company's website following the conference.

About Vor Biopharma

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells. For more information please visit www.vorbio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning the Private Securities Litigation Reform Act of 1995. The words believe, continue, could, estimate, expect, intend, may, plan, potential, project, should, target, will, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding Vors (the Company) platforms potential to treat patients suffering from acute myeloid leukemia. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Companys product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Companys foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption Risk Factors included in the Companys Annual Report on Form 10-K for the year endedDecember 31, 2020, which is on file with the Securities and Exchange Commission (SEC), and in other filings that the Company make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Investor Contact: Chris BrinzeyWestwicke, an ICR Company+1 339-970-2843chris.brinzey@westwicke.com

Media Contact: Rebecca Spalding Ten Bridge Communications +1 646-509-3831rebecca@tenbridgecommunications.com